Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Outset Medical, Inc. is a medical technology company operating in the medical devices and renal care industries, focused on transforming dialysis delivery through automation and usability improvements. The company designs, manufactures, and markets innovative dialysis systems intended to reduce complexity, labor, and infrastructure requirements associated with traditional dialysis treatment.
Outset Medical’s primary product and revenue driver is the Tablo Hemodialysis System, an integrated dialysis platform designed for use across acute care hospitals, dialysis clinics, and home settings. The company primarily serves healthcare providers, including hospitals and dialysis centers, as well as patients transitioning to home hemodialysis. Its strategic positioning centers on offering an all-in-one, software-driven system that simplifies setup, training, and operation compared to conventional dialysis machines. Founded in 2003, Outset Medical evolved from early-stage development into a commercial-stage company and completed its initial public offering in 2020, expanding its installed base and clinical footprint thereafter.
Business Operations
Outset Medical operates as a single-reportable segment focused on the development and commercialization of dialysis technology. Revenue is generated through the sale and leasing of the Tablo Hemodialysis System, recurring sales of disposable cartridges and consumables, and service-related offerings. The system integrates water purification, dialysate production, and treatment delivery into one device, reducing the need for dedicated water rooms and complex plumbing.
The company conducts sales and clinical support primarily in the United States, with expanding international operations. Outset Medical controls its core product design, software development, and regulatory strategy, while relying on a combination of internal manufacturing oversight and third-party suppliers. The company operates through its wholly owned subsidiary, Outset Medical Technology, Inc., which holds key operating assets and intellectual property.
Strategic Position & Investments
Outset Medical’s strategic direction emphasizes expanding adoption of the Tablo Hemodialysis System across care settings, particularly in home hemodialysis, which is aligned with broader healthcare policy initiatives supporting home-based care. Growth initiatives include increasing the installed base, driving recurring consumables revenue, and enhancing software capabilities through iterative product updates.
The company has made targeted investments in clinical studies, regulatory clearances, and manufacturing scale rather than large acquisitions. Strategic efforts also include partnerships with dialysis providers and healthcare systems to support deployment and training. Emerging focus areas include remote monitoring, data analytics, and digital connectivity to improve treatment oversight and patient outcomes, though commercialization timelines for newer capabilities vary by market and regulatory environment.
Geographic Footprint
Outset Medical is headquartered in the United States, with its principal executive offices in California. The company’s largest market presence is in North America, where the majority of its installed base, revenue, and clinical partnerships are located.
Internationally, Outset Medical has expanded into select markets in Europe and other regions through regulatory approvals and distributor relationships. While international revenue remains a smaller portion of total sales compared to the U.S., the company continues to invest in regulatory, commercial, and clinical infrastructure to support broader global adoption over time.
Leadership & Governance
Outset Medical was founded by Leslie Trigg, who played a central role in shaping the company’s mission to simplify dialysis care through design and technology. The leadership team emphasizes patient-centric innovation, operational discipline, and long-term adoption across care settings.
Key executives include:
- Leslie Trigg – President and Chief Executive Officer
- Nino Trentacost – Chief Financial Officer
- Dr. Ankit Patel – Chief Medical Officer
- Sandy Gu – Chief Accounting Officer
- Aric Jorgenson – Chief Commercial Officer
The company is governed by a board of directors with experience across medical devices, healthcare delivery, and public company operations, supporting oversight, regulatory compliance, and strategic execution.